Abcellera Biologics Inc
ABCL3.160USD
+0.380+13.67%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
944.88MValor de mercado
PerdaP/L TTM
Mais detalhes de Abcellera Biologics Inc Empresa
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Informações de Abcellera Biologics Inc
Código da empresaABCL
Nome da EmpresaAbcellera Biologics Inc
Data de listagemDec 11, 2020
CEOHansen (Carl L.G)
Número de funcionários596
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 11
Endereço150 W 4Th Avenue
CidadeVANCOUVER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalV5Y 1G6
Telefone16045599005
Sitehttps://www.abcellera.com/
Código da empresaABCL
Data de listagemDec 11, 2020
CEOHansen (Carl L.G)
Executivos da empresa Abcellera Biologics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Stephen Quake
Mr. Stephen Quake
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2025Q3
FY2025Q2
FY2024Q2
FY2023Q2
Por EmpresaUSD
Nome
Receita
Proporção
Research fees
8.82M
98.46%
Licensing revenue
138.00K
1.54%
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Research fees
8.82M
98.46%
Licensing revenue
138.00K
1.54%
Distribuição de ações
Atualizado em: dom, 25 de jan
Atualizado em: dom, 25 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Thermopylae Holdings Ltd
18.68%
Baker Bros. Advisors LP
9.20%
Capital World Investors
4.46%
Two Sigma Investments, LP
3.34%
Lecault (Veronique)
3.21%
Outro
61.11%
Investidores
Investidores
Proporção
Thermopylae Holdings Ltd
18.68%
Baker Bros. Advisors LP
9.20%
Capital World Investors
4.46%
Two Sigma Investments, LP
3.34%
Lecault (Veronique)
3.21%
Outro
61.11%
Tipos de investidores
Investidores
Proporção
Corporation
18.68%
Hedge Fund
16.25%
Investment Advisor
9.45%
Individual Investor
4.29%
Investment Advisor/Hedge Fund
3.93%
Research Firm
2.06%
Bank and Trust
0.69%
Pension Fund
0.29%
Sovereign Wealth Fund
0.21%
Outro
44.14%
Participação acionária institucional
Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
315
112.27M
50.73%
-101.09K
2025Q3
340
112.51M
51.75%
-3.28M
2025Q2
368
115.12M
53.94%
-18.45M
2025Q1
420
133.63M
52.62%
-23.37M
2024Q4
441
121.95M
50.14%
+4.83M
2024Q3
440
121.95M
51.59%
-4.54M
2024Q2
439
127.07M
51.27%
-6.55M
2024Q1
432
134.44M
53.43%
-22.43M
2023Q4
425
138.44M
60.93%
-1.40M
2023Q3
426
134.18M
60.12%
-4.59M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Thermopylae Holdings Ltd
55.92M
18.68%
-225.00K
-0.40%
Dec 18, 2025
Baker Bros. Advisors LP
27.53M
9.2%
--
--
Sep 30, 2025
Capital World Investors
13.36M
4.46%
--
--
Sep 30, 2025
Two Sigma Investments, LP
9.99M
3.34%
+1.81M
+22.09%
Sep 30, 2025
Lecault (Veronique)
9.61M
3.21%
--
--
Apr 01, 2025
ArrowMark Colorado Holdings, LLC
4.11M
1.37%
--
--
Sep 30, 2025
Renaissance Technologies LLC
3.36M
1.12%
+53.30K
+1.61%
Sep 30, 2025
Tang Capital Management, LLC
2.60M
0.87%
--
--
Sep 30, 2025
Morgan Stanley & Co. LLC
2.56M
0.85%
+1.79M
+234.13%
Sep 30, 2025
Millennium Management LLC
2.43M
0.81%
-967.85K
-28.49%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Genomics Immunology and Healthcare ETF
2.64%
Virtus LifeSci Biotech Clinical Trials ETF
1.19%
ProShares Ultra Nasdaq Biotechnology
0.16%
Invesco Nasdaq Biotechnology ETF
0.16%
SPDR S&P International Small Cap ETF
0.12%
iShares Biotechnology ETF
0.11%
Invesco RAFI Developed Mkts ex-US SM ETF
0.05%
Avantis US Small Cap Equity ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
Ver Mais
iShares Genomics Immunology and Healthcare ETF
Proporção2.64%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção1.19%
ProShares Ultra Nasdaq Biotechnology
Proporção0.16%
Invesco Nasdaq Biotechnology ETF
Proporção0.16%
SPDR S&P International Small Cap ETF
Proporção0.12%
iShares Biotechnology ETF
Proporção0.11%
Invesco RAFI Developed Mkts ex-US SM ETF
Proporção0.05%
Avantis US Small Cap Equity ETF
Proporção0.01%
SPDR Portfolio Developed World ex-US ETF
Proporção0.01%
Fidelity Nasdaq Composite Index ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
